Ann: SCENESSE launched in Europe-CUV.AX, page-13

Of course earnings are going to be the main driver, and even further down the track FDA approval, but as to a near term catalyst for some positive move I think inclusion into the ASX 300 could have the potential to be a pleasant surprise.
I'm pretty sure ASX 300 inclusion would make it available to a whole lot more funds than simply All Ords inclusion, and as I said due to the thin volume being traded, it wouldn't take very many newly interested parties to get it going in the right direction.
As to dropping 20% after All Ords inclusion. I think that's probably more to do with the fact that it happened smack bang in the middle of the major dowtrend/selldown since first approval back in Oct/Nov 2014. Knowing that there was someone there willing to sell off into any strength certainly wasn't helping sentiment towards the stock at the time.
Anyway I guess its all academic because as I said it may not even happen, but something else to maybe look forward to.